Dados B3 › EQTL3 × CPLE3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | EQTL3 | CPLE3 | year |
|---|---|---|---|
| ROE | 6.5% | 11.0% | 2025 |
| ROIC | 9.3% | 10.5% | 2025 |
| ROA | 2.2% | 4.6% | 2025 |
| Gross margin | 26.1% | 21.7% | 2025 |
| EBIT margin | 15.6% | 19.3% | 2025 |
| Net margin | 4.8% | 10.3% | 2025 |
| Net debt/EBITDA | 3.90x | 2.59x | 2025 |
| Current ratio | 1.49x | 0.98x | 2025 |
| Revenue growth (1y) | 19.0% | 15.3% | 2025 |
| Revenue growth (5y CAGR) | 23.8% | 7.0% | 2025 |
| Piotroski F-Score | 5/9 | 6/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | EQTL3 | CPLE3 | year |
|---|---|---|---|
| P/E | 32.35x | 16.52x | 2025 |
| P/B | 2.11x | 1.92x | 2025 |
| EV/EBITDA | 8.72x | 9.39x | 2025 |
| FCF yield | -7.6% | 6.4% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:07 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it